文献速递核素与放射性配体治疗肿瘤 PET/CT

新辅助177Lu-DOTATATE PRRT治疗局部晚期不可切除胃肠胰神经内分泌肿瘤的手术可行性、决定因素及总体疗效

Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2021-02-26

该研究评估了177Lu-DOTATATE肽受体放射性核素治疗(PRRT)在胃肠胰神经内分泌肿瘤(GEP-NET)新辅助治疗中的作用,并分析原发肿瘤变为可切除的相关因素。57例因血管受累不可切除的患者接受177Lu-DOTATATE治疗(每周期7.4 GBq),15例(26.3%)转为可切除,2年无进展生存率组1为95%、组2为90%,合并2年总生存率为92.1%。

要点

  • 新辅助177Lu-DOTATATE可使26.3%的不可切除GEP-NET原发肿瘤转为可切除。
  • 十二指肠NET、无区域淋巴结受累、原发瘤<5 cm等与可切除率较高相关。
  • PRRT后症状、生化、分子影像和 anatomic 影像的完全或部分缓解率分别为84%、40%、31%、40%。

核心结论

  • 在因血管受累而原发肿瘤不可切除的GEP-NET患者中(伴或不伴肝转移),部分患者经177Lu-DOTATATE治疗后原发肿瘤转为可切除,提示可考虑新辅助PRRT。
  • 177Lu-DOTATATE PRRT后观察到有效的症状控制、良好的形态学和功能影像缓解以及持久的PFS和OS,可能降低这类患者的发病率和死亡率。

研究设计与样本

  • 研究纳入57例既往未手术、原发肿瘤因血管受累不可切除(采用美国国家综合癌症网络胰腺导管腺癌标准定义)的GEP-NET患者。
  • 患者分为两组:无肝转移组(组1,23例)和肝转移可潜在切除组(组2,34例)。
  • 177Lu-DOTATATE每周期剂量为7.4 GBq(200 mCi),联合混合氨基酸肾脏保护。
  • 在PRRT疗程中3个不同时间点采用三期对比增强腹部CT评估手术可切除性。

主要发现

  • 57例中15例(26.3%)原发肿瘤由不可切除转为可切除(组1 7例,组2 8例)。
  • 按症状、生化、分子影像和解剖影像标准,PRRT完全或部分缓解分别为48例(84%)、23例(40%)、18例(31%)和23例(40%)。
  • 组1和组2的2年PFS估计率分别为95%和90%;两组合并2年OS为92.1%。

关键数值与推荐

  • 原发肿瘤为十二指肠神经内分泌肿瘤、无区域淋巴结受累、原发肿瘤小于5 cm、肝转移灶不大于1.5 cm、肝转移灶不超过3个、原发肿瘤18F-FDG SUVmax小于5的患者,PRRT后原发肿瘤可切除率显著更高。
  • 采用χ2检验分析变量与原发肿瘤可切除性的关联,P值小于0.05认为有统计学意义。

临床怎么用

  • 对于因血管受累不可切除的GEP-NET原发肿瘤,可考虑新辅助177Lu-DOTATATE PRRT以争取手术切除机会。
  • 具有十二指肠NET、无区域淋巴结受累、原发瘤<5 cm、肝转移灶≤1.5 cm且≤3个、原发瘤18F-FDG SUVmax<5等特征的患者更可能从新辅助PRRT中获益转为可切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We assessed 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in the neoadjuvant setting in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We also evaluated the variables associated with resectability of the primary tumor after PRRT. Methods: This study included 57 GEP-NET patients who had a primary tumor that was unresectable (because of vascular involvement as defined using the pancreatic ductal adenocarcinoma criteria of the National Comprehensive Cancer Network) and who underwent 177Lu-DOTATATE therapy without any prior surgery. They were categorized into 2 groups: 23 patients without liver metastases (group 1) and 34 patients with potentially resectable liver metastases (group 2). 177Lu-DOTATATE was administered with mixed amino acid-based renal protection at a dose of 7.4 GBq (200 mCi) per cycle. Surgical resectability was evaluated using triphasic contrast-enhanced abdominal CT imaging at 3 different time points during the PRRT course. Four broad categories of overall PRRT response were evaluated. The Kaplan-Meier product-limit method was used to calculate progression-free survival (PFS) and overall survival (OS). Associations between variables and a resectable primary tumor after PRRT were analyzed using the χ2 test, with a P value of less than 0.05 considered statistically significant. Results: After 177Lu-DOTATATE therapy, the unresectable primary tumor became resectable in 15 of 57 (26.3%) patients (7 patients in group 1 and 8 patients in group 2). A complete or partial response to PRRT was seen in 48 patients (84%), 23 patients (40%), 18 patients (31%), and 23 patients (40%) using symptomatic, biochemical, molecular imaging, and anatomic imaging criteria, respectively. Estimated rates of PFS were 95% and 90% at 2 y in groups 1 and 2, respectively. The 2-y OS of the 2 groups combined was 92.1%. The rate at which the primary tumor was resectable after PRRT was significantly higher in patients who had duodenal neuroendocrine tumors, patients who had GEP-NETs with no regional lymph node involvement, patients for whom the primary tumor was smaller than 5 cm, patients for whom liver metastases were no larger than 1.5 cm, patients for whom there were no more than 3 liver metastases, and patients for whom 18F-FDG uptake in the primary tumor had an SUVmax of less than 5. Conclusion: In a moderate fraction of GEP-NET patients, with or without liver metastases, whose primary tumor was unresectable because of vascular involvement, the primary tumor converted from unresectable to resectable after 177Lu-DOTATATE therapy, signifying that neoadjuvant PRRT can be considered in such patients. The effective control of symptoms, favorable morphologic and functional imaging response, and durable PFS and OS that we observed after 177Lu-DOTATATE PRRT may lead to less morbidity and mortality in these patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Parghane RV, Bhandare M, Chaudhari V, et al. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2021. PMID: 33637590. doi:10.2967/jnumed.120.258772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。